Privia Health Group (PRVA)
(Delayed Data from NSDQ)
$18.26 USD
+0.27 (1.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.24 -0.02 (-0.11%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Privia Health Group, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,658 | 1,357 | 966 | 817 | 786 |
Cost Of Goods | 1,496 | 1,222 | 903 | 734 | 718 |
Gross Profit | 162 | 135 | 64 | 83 | 68 |
Selling & Adminstrative & Depr. & Amort Expenses | 141 | 154 | 281 | 57 | 52 |
Income After Depreciation & Amortization | 21 | -19 | -217 | 25 | 16 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | -8 | -1 | 1 | 2 | 7 |
Pretax Income | 29 | -19 | -219 | 23 | 9 |
Income Taxes | 8 | -7 | -28 | -7 | 1 |
Minority Interest | -2 | -3 | -2 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 21 | -12 | -191 | 31 | 8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 23 | -9 | -188 | 31 | 8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 27 | -14 | -215 | 27 | 18 |
Depreciation & Amortization (Cash Flow) | 7 | 5 | 3 | 2 | 2 |
Income After Depreciation & Amortization | 21 | -19 | -217 | 25 | 16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 124.69 | 110.70 | 102.95 | NA | NA |
Diluted EPS Before Non-Recurring Items | 0.19 | -0.08 | -1.56 | NA | NA |
Diluted Net EPS (GAAP) | 0.19 | -0.08 | -1.83 | NA | NA |
Fiscal Year end for Privia Health Group, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 440.83 | 417.28 | 413.35 | 386.28 |
Cost Of Goods | NA | 401.79 | 375.55 | 371.92 | 346.99 |
Gross Profit | NA | 39.04 | 41.74 | 41.43 | 39.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 37.62 | 36.20 | 34.45 | 32.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.42 | 5.54 | 6.98 | 6.71 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | -2.85 | -2.89 | -0.82 | -1.81 |
Pretax Income | NA | 4.27 | 8.43 | 7.80 | 8.53 |
Income Taxes | NA | 1.94 | 2.49 | 1.44 | 2.13 |
Minority Interest | NA | -0.51 | 0.30 | -0.91 | -0.92 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 2.32 | 5.94 | 6.36 | 6.40 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 2.84 | 5.64 | 7.27 | 7.32 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 124.83 | 124.92 | 124.57 | 124.33 |
Diluted EPS Before Non-Recurring Items | NA | 0.02 | 0.05 | 0.06 | 0.06 |
Diluted Net EPS (GAAP) | NA | 0.02 | 0.05 | 0.06 | 0.06 |